IBUPROFEN TABLET
Država: Kanada
Jezik: angleščina
Source: Health Canada
Lastnosti izdelka
(SPC)
26-02-2020
Nekateri dokumenti za ta izdelek trenutno niso na voljo, pošljete lahko zahtevo v našo stranko in obvestili vas bomo takoj, ko jih bomo lahko pridobili.
Pošlji zahtevo.
Pošlji zahtevo.
Aktivna sestavina:
IBUPROFEN
Dostopno od:
ANGITA PHARMA INC.
Koda artikla:
M01AE01
INN (mednarodno ime):
IBUPROFEN
Odmerek:
200MG
Farmacevtska oblika:
TABLET
Sestava:
IBUPROFEN 200MG
Pot uporabe:
ORAL
Enote v paketu:
100
Tip zastaranja:
OTC
Terapevtsko območje:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Povzetek izdelek:
Active ingredient group (AIG) number: 0108883004; AHFS:
Status dovoljenje:
APPROVED
Datum dovoljenje:
2020-04-23
Lastnosti izdelka
_Page 1 / 40_
PRODUCT MONOGRAPH
IBUPROFEN
Ibuprofen Tablets USP
200mg and 400 mg
Non-Steroidal Anti-inflammatory Drug
Analgesic, Antipyretic Agent
Angita Pharma Inc.
1310 Nobel Street,
Boucherville,
Québec Canada, J4B 5H3
Date of Preparation: February 26, 2020
Control # 236574
_Page 2 / 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINCAL USE
...........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
9
DRUG INTERACTIONS
..............................................................................................................
12
DOSAGE AND ADMINISTRATION
..........................................................................................
15
OVERDOSAGE
..................................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
16
STORAGE AND STABILITY
......................................................................................................
17
SPECIAL HANDLING INSTRUCTIONS
..................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 18
PART II: SCIENTIFIC INFORMATION
................................................................................
19
PHARMACEUTICAL INFORMATION
..................
Preberite celoten dokument
